Does semaglutide cause depression? Current evidence does not show that it does. The FDA's comprehensive 2026 review found no increased risk of depression, suicidal thoughts, or related psychiatric events with GLP-1 medicines. That is reassuring, but it does not mean an individual mood change should be dismissed. New or worsening depression deserves a prompt conversation with the prescriber; suicidal thoughts require immediate help.
The distinction matters: a safety signal asks researchers to investigate. It does not establish that a medicine caused the event.
Does semaglutide cause depression? The regulator record
In January 2024, the FDA said its preliminary evaluation found no evidence that GLP-1 medicines caused suicidal thoughts or actions. Reports in the agency's adverse-event database often lacked detail and involved other possible causes. Because the number of events in trials was small, the agency could not yet rule out a small risk and continued reviewing.
The European Medicines Agency reached a similar point in April 2024. After considering clinical trials, postmarketing reports, nonclinical evidence, and observational studies, its Pharmacovigilance Risk Assessment Committee concluded that the evidence did not support a causal association between semaglutide and suicidal or self-injurious thoughts or actions.
The FDA closed the loop on January 13, 2026. Its final review combined 91 placebo-controlled trials involving 107,910 people and found no increase in suicidal behavior or ideation, depression, anxiety, irritability, or psychosis. A separate Sentinel analysis of 2,243,138 people with type 2 diabetes found no increased intentional self-harm risk for GLP-1 users versus SGLT2 users. The agency requested removal of the suicidal-behavior warning; the February 2026 Wegovy label records that removal.
What the human studies found
The regulator conclusions line up with several kinds of human evidence, although each has limits.
A 2024 Nature Medicine study followed electronic health records for six months. Among 240,618 people with overweight or obesity, semaglutide was associated with lower recorded risk of first suicidal ideation than non-GLP-1 weight-management drugs (hazard ratio 0.27) and lower recurrent ideation (hazard ratio 0.44). The pattern was reproduced in 1,589,855 people with type 2 diabetes (Wang et al., Nature Medicine 2024). Because this was an observational study, it shows association, not that semaglutide protects mental health.
A pooled analysis of the randomized STEP 1, 2, and 3 trials covered 3,377 participants, while STEP 5 added 304 participants followed for two years. Suicidal ideation or behavior was reported by 1% or fewer in each group, with no difference between semaglutide and placebo. Depression scores changed slightly in semaglutide's favor, but the authors said the difference was not clinically meaningful (Wadden et al., JAMA Internal Medicine 2024). These trials largely excluded people with recent major depression, a suicide attempt, or other major psychopathology, so they answer less about those higher-risk groups.
A 2025 insurance-claims study compared 16,822 new semaglutide users with 11,986 users of other weight-management drugs. At six months, adjusted suicidal-ideation risk was 0.08% versus 0.05%; the 0.02-percentage-point risk difference had a confidence interval from −0.02 to 0.07 percentage points. The authors found no apparent increase but stressed that rare events and claims coding left uncertainty (Her et al., Diabetes, Obesity and Metabolism 2025).
Those data address semaglutide or the GLP-1 class; they do not prove that every medicine has an identical psychiatric profile. For readers weighing two common options, tirzepatide versus semaglutide covers the clinical differences that can shape a provider's choice.
Why mood changes are still reported
Reports can be real experiences without proving one common drug effect. Depression already overlaps with obesity and type 2 diabetes. Sleep disruption, nausea, reduced food intake, rapid changes in routine, other medications, and life events may also affect mood during the same period. Semaglutide-related fatigue can feel like low energy, but fatigue alone is not the same as depression.
Researchers also have biologically plausible ideas pointing in both directions. GLP-1 signaling reaches brain circuits involved in appetite and reward, so a sharp change in food reward could feel unsettling to some people. Other hypotheses propose that better insulin sensitivity and lower inflammatory signaling could support mood. A 2025 systematic review found mostly favorable preclinical results but mixed observational evidence, and only one of three clinical studies showed a statistically significant antidepressant effect (Li et al., European Neuropsychopharmacology 2025). None of these hypotheses makes semaglutide an antidepressant or establishes depression as a drug effect.
What a prescriber needs to know
A useful intake covers current depression or anxiety symptoms, prior self-harm or suicide attempts, bipolar disorder, eating disorders, current psychiatric medications, and recent treatment changes. That history matters because the strongest weight-management trials did not represent every psychiatric population. It also gives the prescriber a baseline for separating a new change from a longstanding pattern.
A history of depression does not, by itself, answer whether semaglutide is appropriate. Nor does a reassuring population average predict one person's experience. The clinical decision depends on current stability, treatment supports, other medicines, and a plan for follow-up. Is semaglutide safe? places this question alongside the medication's other established risks.
What to do about a mood change
Persistent sadness, loss of interest, hopelessness, unusual agitation, or a marked change in sleep, behavior, or functioning warrants contact with the prescribing clinician. The prescriber can look at timing, dose changes, nutrition, physical side effects, other medications, and the possibility of an unrelated depressive episode. They decide whether treatment continues, pauses, or changes.
Suicidal thoughts are urgent regardless of the suspected cause. In the United States, call or text 988 for the Suicide & Crisis Lifeline; call 911 or go to an emergency department if there is immediate danger. A regulator's population-level finding should never be used to explain away an individual crisis.
The prescription route keeps someone accountable
Semaglutide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision belongs between the patient and the doctor.
A licensed provider reviews every request, and not everyone qualifies. That review is where mental-health history, current medications, side effects, and follow-up become part of the same decision rather than separate online questions.